CTOs on the Move

DaVita Rx

www.davitarx.com

 
DaVita RxⓇ is the first and largest full-service pharmacy created specifically for the unique needs of kidney patients, and has expanded to other complex conditions as well. We make it easier for patients to get their medications and follow their drug regimens. We give providers a whole new way to improve patient care.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.davitarx.com
  • 1234 Lakeshore Drive Suite 200
    Coppell, TX USA 75019
  • Phone: 972.538.8100

Executives

Name Title Contact Details

Similar Companies

Hs Pharma

Hs Pharma is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Helvoet Pharma USA

Helvoet Pharma USA is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greater Cincinnati Behavioral Health Services

Cincinnati Comprehensive Mental Health Agency helping people through many services and a staff of more than 500 highly skilled professionals.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.